Kepler Capital analyst David Cerdan upgraded Qiagen (QGEN) to Buy on March 9 and set a price target of EUR51.00. The company’s shares closed last Wednesday at $46.96.
Cerdan has an average return of 3.2% when recommending Qiagen.
According to TipRanks.com, Cerdan is ranked #3870 out of 7358 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $57.48 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.00 and a one-year low of $36.16. Currently, Qiagen has an average volume of 943.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.